[14C]normacromerine fate in the rat

Area of Science:

• Pharmacology
• Toxicology
• Metabolism studies

Background:

• Normacromerine is a dimethoxylated phenethylamine derivative.
• It possesses putative hallucinogenic properties.
• Understanding its biological fate is crucial for assessing its potential effects.

Purpose of the Study:

• To evaluate the biological fate and excretion pathways of [14C] normacromerine in male Sprague-Dawley rats.
• To quantify the elimination of radioactivity and identify major metabolites.
• To compare normacromerine's metabolic profile with other phenethylamines.

Main Methods:

• Administration of [14C] normacromerine (100 mg/kg, orally) to male Sprague-Dawley rats.
• Collection and analysis of urine and feces over a 24-hour period.
• Quantification of radioactivity and identification of normacromerine in excreta using radiodetection methods.

Main Results:

• Urine was the primary route of elimination, accounting for 50% of the administered carbon-14 within 24 hours.
• Normacromerine was detected in urine at 8 hours (30% of radioactivity) but was nondetectable by 24 hours.
• Fecal excretion was less than 10% of the dose, and no carbon-14 dioxide (14CO2) expiration was observed.

Conclusions:

• Normacromerine is primarily excreted via urine in rats.
• The parent compound is metabolized or further eliminated within 24 hours.
• Comparative studies with other phenethylamines may aid in evaluating normacromerine's hallucinogenic potential.